Russell Investments Group Ltd. Acquires 209,676 Shares of Abbott Laboratories $ABT

Russell Investments Group Ltd. boosted its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 15.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,590,548 shares of the healthcare product maker’s stock after purchasing an additional 209,676 shares during the period. Russell Investments Group Ltd.’s holdings in Abbott Laboratories were worth $157,311,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ABT. PBU The Pension Fund of Early Childhood & Youth Educators boosted its stake in Abbott Laboratories by 11.5% in the third quarter. PBU The Pension Fund of Early Childhood & Youth Educators now owns 133,175 shares of the healthcare product maker’s stock valued at $13,162,000 after acquiring an additional 13,731 shares during the last quarter. Nikulski Financial Inc. increased its stake in shares of Abbott Laboratories by 5.2% during the 3rd quarter. Nikulski Financial Inc. now owns 14,962 shares of the healthcare product maker’s stock worth $1,479,000 after purchasing an additional 746 shares during the last quarter. Three Bridge Wealth Advisors LLC purchased a new stake in shares of Abbott Laboratories during the 3rd quarter worth approximately $54,000. Gagnon Securities LLC bought a new stake in shares of Abbott Laboratories in the 3rd quarter worth approximately $471,000. Finally, Maryland State Retirement & Pension System raised its holdings in shares of Abbott Laboratories by 15.0% in the 3rd quarter. Maryland State Retirement & Pension System now owns 106,690 shares of the healthcare product maker’s stock worth $10,544,000 after purchasing an additional 13,924 shares during the period. Institutional investors own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In other news, EVP Mary Moreland sold 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $116.00, for a total value of $406,000.00. Following the completion of the transaction, the executive vice president directly owned 100,791 shares in the company, valued at approximately $11,691,756. This trade represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of ABT opened at $108.59 on Monday. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $132.02. The stock’s 50-day simple moving average is $103.93 and its 200 day simple moving average is $101.74. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.00 and a current ratio of 1.45. The stock has a market capitalization of $188.08 billion, a price-to-earnings ratio of 40.52, a price-to-earnings-growth ratio of 1.90 and a beta of 0.54.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.42. The business had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.30 EPS. Research analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 94.03%.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ABT. JPMorgan Chase & Co. reduced their price objective on Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating for the company in a report on Thursday, October 22nd. Barclays assumed coverage on Abbott Laboratories in a research note on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 target price on the stock. Robert W. Baird upped their price target on Abbott Laboratories from $121.00 to $123.00 and gave the company an “outperform” rating in a research report on Thursday, October 22nd. TD Cowen cut their price target on Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating for the company in a research note on Thursday, October 22nd. Finally, Argus lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $118.32.

Read Our Latest Stock Report on Abbott Laboratories

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Further Reading

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.